Topics

TOPICS

ANEMIA

Cell-Free DNA May Be Involved in Disease Pathophysiology in Sickle Cell Disease

Haplo-Identical Donors as an Alternative for Patients With Fanconi Anemia

BLEEDING DISORDERS

Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia

Recombinant Factor VIII-Fc Fusion Protein for Hemophilia A Management

GENERAL HEMATOLOGY

Platelets May Be Treatment Target for Lupus

Electronic Self-Reporting Tool Improves Symptom Management During Cancer Treatment

LEUKEMIA

BTK Inhibitors for CLL Lower Response to Some Vaccines

Pre-Transplantation MRD Status Predicts Survival in Acute Leukemia

LYMPHOMA

Outcomes of PET4-Guided Omission of Radiotherapy Consolidation in Hodgkin Lymphoma

R-MegaCHOEP vs R-CHOEP-14 in Newly Diagnosed Aggressive B-Cell Lymphoma

MYELODYSPLASTIC SYNDROMES

Paroxysmal Nocturnal Hemoglobinuria Clones Positive Predictor in Myelodysplastic Syndromes, Aplastic Anemia

Older Patients With MDS Have Survival Benefit From Transplantation

MYELOMA

Daratumumab Not Cost-Effective for Multiple Myeloma

Ixazomib in an Oral Triplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma

SIDE EFFECT MANAGEMENT

ONS Releases Guidelines on the Management of Cancer Treatment–Related Hot Flashes

New NCCN Patient Guidelines Feature Immunotherapy, CAR-T Side Effects

THALASSEMIAS

Dose of Total Body Irradiation With Transplantation for Hemoglobinopathies

Deferiprone Non-Inferior to Deferasirox for Patients With Pediatric Hemoglobinopathy

THROMBOTIC DISORDERS

Rivaroxaban May Be Clinically Superior to LMWH in Patients With Cancer-Associated Thrombosis

Evaluating the Role of Platelets in Ischemia-Reperfusion Injury Post-Stroke

Next post in Myeloma

$A pooled analysis of 3 combination drug regimens used to treat refractory/relapsed multiple myeloma$

Ixazomib in an Oral Triplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma